**Supplementary Fig. 5** Ado/A2AR impact p-S6 activation. The data represented in this figure were obtained analyzing CD8+ T cells stimulated for 3h by anti-CD3/anti-CD28 coated beads under the distinct described conditions.(**a**) Representative example of p-S6 expression detected by flow cytometry after treatment with Ado or the depicted combination of A2AR agonist (CGS 21680) and A2AR/A2BR antagonists (ZM 241385 and PSB 1115). (**b**) Representative western blot analysis of p-S6 and S6 after treatment with Ado alone or combined with the A2AR antagonist (ZM 241385) or the PKA inhibitor (KT570), Rapamycin, the AKT1/2 inhibitor (MK2206). α-Tubulin was detected as a loading control. *n* = 3. (**c**) Representative example of p-AktSer473 expression detected by flow cytometry in resting condition or after treatment with Ado. (**d**) Representative western blot analysis of p-AktSer473 and AktSer473 after treatment with Ado alone or combined with the A2AR antagonist (ZM 241385) or the PKA inhibitor (KT570), Rapamycin, the AKT1/2 inhibitor (MK2206). α-Tubulin was detected as a loading control. *n* = 3. (**e**) Cumulative data showing the fold change in p-AktSer473 expression after treatment with the indicated combinations of Ado, A2AR agonist (CGS 21680), A2AR/A2BR antagonists (ZM 241385 and PSB 1115, respectively) or the AKT1/2 inhibitor (MK2206). The 25th to 75th percentiles, the median and min-max of the values are represented; *n* = 7. (**f**) Cumulative data showing the fold change in p-S6 expression by memory CD8+ T cell subsets (TCM, TEM, TEMRA) in presence of Ado or the A2AR selective agonist CGS 21680. The 25th to 75th percentiles, the median and min-max of the values are represented; *n* = 14 and *n* = 12 from left to right. \*\**P* < 0.01, \*\*\**P* < 0.001, \*\*\*\**P* < 0.0001, one-way ANOVA test.